RhumbLine Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,112
| Closed | -$2.46K | – | 4392 |
|
|
2023
Q2 | $2.46K | Buy |
+1,112
| New | +$2.31K | ﹤0.01% | 4187 |
|
|
2022
Q2 | – | Sell |
-44,588
| Closed | -$132K | – | 3293 |
|
|
2022
Q1 | $132K | Sell |
44,588
-7,567
| -15% | -$28.5K | ﹤0.01% | 2842 |
|
|
2021
Q4 | $234K | Sell |
52,155
-731
| -1% | -$3.47K | ﹤0.01% | 2789 |
|
|
2021
Q3 | $257K | Buy |
52,886
+2,150
| +4% | +$11.8K | ﹤0.01% | 2831 |
|
|
2021
Q2 | $346K | Sell |
50,736
-3,491
| -6% | -$28.2K | ﹤0.01% | 2728 |
|
|
2021
Q1 | $383K | Sell |
54,227
-1,840
| -3% | -$13.3K | ﹤0.01% | 2609 |
|
|
2020
Q4 | $351K | Buy |
56,067
+3,579
| +7% | +$21.1K | ﹤0.01% | 2601 |
|
|
2020
Q3 | $284K | Sell |
52,488
-8,585
| -14% | -$42.5K | ﹤0.01% | 2542 |
|
|
2020
Q2 | $319K | Buy |
61,073
+12,039
| +25% | +$53.5K | ﹤0.01% | 2549 |
|
|
2020
Q1 | $154K | Hold |
49,034
| – | – | ﹤0.01% | 2668 |
|
|
2019
Q4 | $198K | Buy |
49,034
+4,616
| +10% | +$16K | ﹤0.01% | 2754 |
|
|
2019
Q3 | $192K | Sell |
44,418
-300
| -0.7% | -$1.2K | ﹤0.01% | 2758 |
|
|
2019
Q2 | $178K | Buy |
44,718
+4,380
| +11% | +$20.8K | ﹤0.01% | 2823 |
|
|
2019
Q1 | $216K | Sell |
40,338
-860
| -2% | -$5.55K | ﹤0.01% | 2716 |
|
|
2018
Q4 | $211K | Buy |
41,198
+13,733
| +50% | +$104K | ﹤0.01% | 2714 |
|
|
2018
Q3 | $266K | Sell |
27,465
-2,050
| -7% | -$20.7K | ﹤0.01% | 2579 |
|
|
2018
Q2 | $301K | Buy |
29,515
+6,240
| +27% | +$70.6K | ﹤0.01% | 2533 |
|
|
2018
Q1 | $303K | Buy |
23,275
+610
| +3% | +$9.08K | ﹤0.01% | 2430 |
|
|
2017
Q4 | $406K | Sell |
22,665
-5,396
| -19% | -$113K | ﹤0.01% | 2322 |
|
|
2017
Q3 | $704K | Buy |
28,061
+959
| +4% | +$22.3K | ﹤0.01% | 2155 |
|
|
2017
Q2 | $653K | Buy |
27,102
+7,389
| +37% | +$163K | ﹤0.01% | 2167 |
|
|
2017
Q1 | $379K | Buy |
19,713
+2,270
| +13% | +$35.8K | ﹤0.01% | 2381 |
|
|
2016
Q4 | $269K | Buy |
17,443
+1,456
| +9% | +$18.9K | ﹤0.01% | 2540 |
|
|
2016
Q3 | $208K | Buy |
15,987
+2,195
| +16% | +$29.1K | ﹤0.01% | 2659 |
|
|
2016
Q2 | $192K | Buy |
13,792
+1,510
| +12% | +$22.2K | ﹤0.01% | 2762 |
|
|
2016
Q1 | $186K | Buy |
12,282
+65
| +0.5% | +$994 | ﹤0.01% | 2757 |
|
|
2015
Q4 | $232K | Buy |
12,217
+1,810
| +17% | +$34.5K | ﹤0.01% | 2716 |
|
|
2015
Q3 | $198K | Buy |
10,407
+477
| +5% | +$11.9K | ﹤0.01% | 2792 |
|
|
2015
Q2 | $256K | Buy |
+9,930
| New | +$282K | ﹤0.01% | 2758 |
|
RhumbLine Advisers's PRTK Position: Q3 2023 in Review
RhumbLine Advisers sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 1,112 shares — an estimated $2.46K sold.
RhumbLine Advisers first reported a position in PRTK in Q2 2015 and held it in 29 quarters. The position peaked at $704K in Q3 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- RhumbLine Advisers reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- RhumbLine Advisers sold 1,112 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $2.46K.
- RhumbLine Advisers first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 29 quarters.
- RhumbLine Advisers's Paratek Pharmaceuticals, Inc. position peaked at $704K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.